Abstract: (−)-∆9-Tetrahydrocannabinol is the principal psychoactive component of the cannabis plant and also the active ingredient in some prescribed drugs. To detect and control misuse and monitor administration in clinical settings, reference samples of the native drugs and their metabolites are needed. The accuracy of liquid chromatography/mass spectrometric quantification of drugs in biological samples depends among others on ion suppressing/alteration effects. Especially, 13 C-labeled drug analogues are useful for minimzing such interferences. Thus, to provide internal standards for more accurate quantification and for identification purpose, synthesis of [ tetrahydrocannabinol was shortened from three to two steps by employing nitromethane as a co-solvent in condensation with (+)-apoverbenone.
Introduction
(−)-∆ 9 -Tetrahydrocannabinol (∆ 9 -THC, 1), is a product of the female flowering parts of Cannabis sativa (marijuana), and is the main psychoactive substance in the plant. As compound 1 and analogues act on the cannabinoid receptors, the cannabinoid group of compounds is also medicinally useful. Among others, development have led to the ∆ 9 -THC-containing drug Sativex ® , indicated for treatment of moderate to severe spasticity due to multiple sclerosis [1] , and Marinol ® , used in the treatment of chemotherapy-induced nausea and vomiting [2] . The ∆ 9 -THC analogue Nabilone™, also an approved drug, is indicated efficient in treatment of the same conditions [2, 3] . However, recreational use and continued illicit use of marijuana have increased the importance of having methods to determine usage by individuals.
In vivo ∆ 9 -THC (1) undergoes phase I metabolism to yield 11-hydroxy-∆ 9 -tetrahydrocannabinol (11-OH-THC, 2) peaking immediately after smoking, Scheme 1. Metabolite 2 is also psychoactive, but is rapidly oxidized to the inactive metabolite (-)-11-nor-9-carboxy-∆ 9 -tetrahydrocannabinol (THC-COOH, 3), which slowly increases and plateaus after 2-4 h [4] . Metabolism occurs mainly in the liver by cytochrome P450 enzymes 2C9, 2C19, and 3A4 [5] . The main urinary metabolites occur as phase II conjugates of glucuronic acid, and less commonly as sulphate, glutathione, amino acids, and fatty acid conjugates. The main site for glucuronidation is the carboxylate at C-11, but 11-OH-THC (2) may undergo phase II metabolism as well.
Scheme 1. Major phase I metabolites derived from ∆ 9 -THC (1).
Efficient analysis of both drugs and their metabolites are required in the fields of pharmacology, clinical toxicology and forensic toxicology, but also for workplace drug testing, testing of driving under the influence of drugs, doping analysis and rehabilitation programs. Since these analyses are often performed by mass spectroscopic techniques, reference samples of the native drug, its main metabolites and suitable standards are needed for identification and quantification purposes. Stable isotope labeled internal standards (SIL IS) are added to correct for error in the sample preparation and co-eluting substances that could alter or suppress the signal [6] . Deuterated internal standards with varying degree of labeling are currently used as IS in quantification of cannabinoids [7] [8] [9] [10] [11] .
However, under certain conditions the MS ionization of the analytes is influenced differently from that of its deuterium labeled analogues, due to slight differences in retention. This potentially leads to inaccuracies in the quantification [12, 13] . Urine analysis of ∆ 9 -THC (1) and its metabolites by LC-MS/MS is especially challenging, due to the presence of unstable compounds and strong adsorption to hydrophobic surfaces and the need for enzymatic pre-processing of the sample prior to analysis. Further, the importance of an effective sample clean-up prior to cannabinoid analysis to remove matrix interferences and maintaining a high extraction efficiency has been highlighted [14] . Also, Scheidweiler et al. [15] concluded that urine samples from different individuals gave matrix effects not observed during method validation, contributing to inaccurate cannabinoid quantification. It is also likely that the challenge with ion suppressing/alteration or matrix effects will be even more pronounced by the use of high resolution techniques such as UHPLC-MS/MS. This indicates that there is a need for a better SIL IS for cannabinoid analysis. 13 C-Labeled IS are particularly suitable for minimizing ion suppression/alteration effects in LC-MS/MS analysis, therefore the quantitative analysis in various biological samples are particularly accurate and reproducible. However, to avoid "overlap" with the natural 13 C in the native compound in MS detection, the number of labeled atoms must preferably be at least three. Recently, the success of substituting deuterated IS with 13 C IS has been shown in the case of amphetamine and methamphetamine quantification [16] . The use of 13 C as labeled compounds as IS is also widely known and appreciated in other fields of analytical chemistry [17] [18] [19] [20] [21] . Based on this background we disclose herein a synthesis of [ 
Results and Discussion

Strategy Selection and Synthesis of [ 13 C 4 ]-Olivetol
Our aim was to find an efficient synthesis of 13 C-labeled (−)-(6aR,10aR)-6,6,9-trimethyl-3-pentyl6a,7,8,10a-tetrahydro-6H-benzo[c]chromen-1-ol, termed Δ 9 -THC (1), and its main urine metabolite Δ 9 -THC-COOH (3). Previously developed routes towards Δ 9 -THC (1) involve both reactions with 5-pentyl-1,3-benzenediol (olivetol) and various chiral natural derived terpenes [22] [23] [24] [25] and asymmetric syntheses [26] [27] [28] . Herein, we have focused on the use of terpenes for introducing the correct stereochemistry. Due to the lengthy and rather complicated synthesis of the terpenes, it was decided to label olivetol. Moreover, labeled olivetol (I) is also a useful building block for the second target, namely Δ 9 -THC-COOH (3). The goal was to introduce at least three [ 13 C] atoms in olivetol, and several strategies were considered, see Scheme 2.
A key intermediate was assumed to be protected 5-(bromomethyl)benzene-1,3-diol derivatives, II, which can be converted to olivetol analogues (I) by metal catalysed coupling [29] or olefination chemistry [30] using IV or V. Another precursor is [ 13 C 6 ]-3,5-dihydroxybenzoic acid (VII), available by synthesis from [ 13 C 6 ]-benzoic acid [31] . Depending on the following strategy (olefination or C-C coupling) additional steps are needed. As the benzoic acid routes appeared long with expected lower 13 C atom efficiency, we decided to prepare an olivetol derivative with four carbons in the alkyl chain by using commercially available [ Trimethylsilyl iodide could also be used, although purification was more tedious in this case. The Wittig strategy using butyltriphenylphosphonium salt in combination with the non-labeled benzaldehyde (V) was also briefly tested. The first step involving formation of the Wittig salt was slow in toluene and needed several days at reflux to reach full conversion. On the other hand both the alkene forming step, and the hydrogenation of the olefin with palladium on carbon as catalyst proceeded smoothly. Thus, by tuning of the first step, this route might be highly useful.
Scheme 2.
Retrosynthetic route to 13 C-labeled olivetol derivatives.
Scheme 3. Synthesis of [ 13 C 4 ]-olivetol (6).
[ 13 C 4 ]-Labeled Δ 9 -THC and Δ 9 -THC-COOH
In the synthesis of [ 13 C 4 ]-Δ 9 -THC (1), [ 13 C 4 ]-olivetol (6) was simply condensed with the terpene 7
in the presence of boron trifluoride as Lewis acid following the procedure of Silverberg et al. [25] , Scheme 4. Alternative acid catalysts for such transformations has been published by Rosati et al. [32] .
After purification by preparative HPLC the product was isolated in 61% yield as a colourless oil (purity >99%). The product gradually darkened upon storage at −20 °C, however, no change in chromatographic purity was noticed. An alternative procedure towards 8 that was previously used in the synthesis of the structurally related compound Nabilone™ [34] was also investigated. By this one-step reaction between (1R,5R)-6,6-dimethylbicyclo[3.1.1]hept-3-en-2-one ((+)-apoverbenone, 11) and 5-(1,1-dimethylheptyl)resorcinol in the presence of aluminum chloride, a low 16% yield was reported [34] . However, we were able to increase the yield in this transformation up to 67% by the use of nitromethane as co-solvent in the condensation between [ 13 C 4 ]-olivetol (6) and 11. Although the exact role of nitromethane has not been investigated it is assumed that the improvement in part is due to increased solubility and mixing of aluminum chloride. Nitromethane has also been reported to modify/reduce the activity of the aluminum chloride, which might also be an important aspect [35] . It should be noted that both of the terpenes 9 and 11 in the end yielded the natural enantiomeric form of (-)-Δ 9 -THC-COOH (3) in contrast to other possible strategies [36] . The precursor 8 was then transformed to [ 13 C 4 ]-Δ 9 -THC-COOH (3) in three operations. Treatment with triisopropylbenzenehydrazine yielded the corresponding hydrazone, which was carefully dried prior to treatment with butyl lithium in n-hexane in the presence of tetramethylethylenediamine (TMEDA) and then gaseous CO 2 . Scrupulously dry and pure reagents were needed in this transformation. Kachensky et al. [37] reported on a 9/1 ratio of Δ 9 /Δ 8 THC-COOH by using a 10% solution of TMEDA. The dilution factor was however not mentioned. Following these conditions, only the Δ 8 -isomer was obtained in our earlier test reactions. This is in line with that observed by Nikas et al. [33] . Decreasing the concentration by fifty percent by addition of more of the TMEDA/n-hexane solvent mixture had a positive effect. The crude product contained a 6/4 ratio of [ 13 C 4 ]-3 and the  8 -regioisomers, which corresponds with that reported by Nikas et al. [32] . Purification was done first by silica-gel column chromatography to remove structurally unrelated impurities, followed by two crystallisations to arrive at a final purity of 97.5%. A chromatogram of the prepared material as compared to the native substance is shown in Figure 2 . Preparative HPLC was used to recover additional
-THC-COOH (3) from the mother liquor giving a total yield of 18%. The enantiomeric excess of Δ 9 -THC-COOH (3) was determined by self-induced non-equivalence by 1 H-NMR spectroscopy of ketone intermediate [ 13 C 4 ]-8 [38] and was found to be 96% ee. 
Experimental Section
Chemicals and Analysis
Bulk solvents were purchased either from LabScan (Gliwice, Poland) or Merck (Darmstadt, Germany). Deuterated solvents were purchased from CDN Isotopes Inc (Pointe-Claire, QC, Canada). All chemicals or reagents used were of highest purity available and purchased from Sigma-Aldrich (Oslo, Norway) or Acros (Geel, Belgium). All solvents and chemicals were used as is without further purification unless otherwise stated. Anhydrous solvents were used as is and stored over activated molecular sieves. The silica-gel used for flash chromatography was Merck silica gel 60 (230-400 mesh 
Synthesis of [ 13 C 4 ]-1-(3,5-Dimethoxyphenyl)pentane (5)
A solution of [ 13 C 4 ]-butyl magnesium bromide (3.50 mmol) cooled to 0-5 °C, generated from [ 13 C 4 ]-butyl bromide and magnesium in ether (3.5 mL, 1 M), and was added dropwise to a mixture of 3,5-dimethoxybenzyl bromide (14, 0.71 g, 3.07 mmol) in diethyl ether (20 mL) and dilithium tetrachlorocuprate (0.1 mL, 0.1 M in tetrahydrofuran) also at 0-5 °C. The reaction was allowed to warm slowly to room temperature and then stirred for 8 h. The reaction mixture was quenched by addition of saturated ammonium chloride solution (5 mL) followed by 10% sulphuric acid (25 mL). The organic layer was separated and the aqueous layer was extracted with diethyl ether (20 mL). The resulting emulsion was passed through glass wool and the organic layers were combined and dried over magnesium sulphate. The product was purified by silica-gel column chromatography (n-heptane/acetone, 93/7, R f = 0. 20 (m, 2H), 1.26-1.51 (m, 3H), 1.56-1.73 (m, 1H) 85 mmol) were added. Anhydrous dichloromethane (15 mL) was added and stirred under an argon atmosphere. The solution was cooled at −5 °C and boron trifluoride diethyl etherate (243 µL, 1 eq) was added. The solution gradually darkened to red. After 20 min, the reaction was quenched with 10% Na 2 CO 3 (5 mL). The layers were separated and the organic layer was washed with 10% Na 2 CO 3 (20 mL). The combined aqueous phases were extracted once with dichloromethane (20 mL). The organic solutions were combined and washed with water (20 mL) and brine (20 mL), and then dried over magnesium sulphate. The crude yield was 1.32 g of a brown oil, which was purified further by preparative HPLC to yield 0.36 g (1.13 mmol, 61%) of 
Synthesis of [
C 4 ]-(4R)-4-(4-pentyl-2,6-dihydroxy-[
C 6 ]-phenyl)-6,6-di-methyl-2-norpinanone (10)
p-Toluenesulphonic acid monohydrate (1.60 g, 8.37 mmol) was added to a degassed solution of [ 13 C 4 ]-olivetol (6, 1.10 g, 5.98 mmol) and (+)-6,6-dimethyl-2,2-diacetoxy-3-norpinene (9, crude mixture, 2.80 g, 11.7 mmol) in chloroform (100 mL) at 0 °C under an argon atmosphere. The reaction mixture was warmed to room temperature and stirred for 3 days. Water was added (2 mL) and the reaction further stirred for 30 min. The mixture was diluted with diethyl ether (30 mL) and washed sequentially with water (20 mL), saturated aqueous sodium bicarbonate (20 mL), and brine (20 mL). The organic phase was dried over magnesium sulphate and the solvent was removed under reduced pressure. The residue obtained was dry flashed on silica-gel (n-heptane/diethyl ether, 55/45) in a Büchner funnel to remove unreacted terpenes. Further purification by silica-gel flash column chromatography, (n-heptane/acetone, 7/3, R f = 0. 
Trimethylsilyl trifluoromethanesulphonate (3.81 mL, 0.3 M solution in nitromethane, 1.14 mmol) was added to a solution of (4R)-4-(4-[ be crystallized from dichloromethane and pentane for higher purity. The spectroscopic properties were identical to that reported in Section 3.6. 1-methylethyl)-2-[(6aR,10aR)-6,6a,7,8,10 ,10a-hexahydro-1-hydroxy-6,6-dimethyl-3-pentyl-9H-dibenzo[b,d]pyran-9-ylidene]hydrazide as a foam which were further dried over phosphorous pentoxide and vacuum overnight. This material was dissolved in a mixture of dry n-hexane freshly distilled over sodium /TMEDA from a new bottle (6 mL, 1/1 ratio) under an argon atmosphere at −78 °C. n-Butyl lithium (387 µL, 0.96 mmol, 2.5 M solution in n-hexane) was added to this solution. The reaction mixture was stirred for 20 min at −78 °C and then it was warmed to −5 °C over a 10 min period and stirred at this temperature for an additional 20 min. The reaction mixture was cooled to −78 °C and a second portion of n-butyl lithium (194 µL, 0.77 mmol) was added. Following the addition, the mixture was stirred for 10 min at −78 °C and then allowed to warm to 0 °C over a 10 min period. Stirring was continued for 20 min at 0 °C or until N 2 evolution ceased, and then dry CO 2 was bubbled into the reaction mixture for 30 min. The pH was adjusted to 2 by the addition of 5% aqueous HCl solution at 0 °C, and the mixture was warmed to room temperature and extracted with diethyl ether (2 × 30 mL). The ethereal solution was washed with brine (20 mL), dried (magnesium sulphate), and the solvent was evaporated under vacuum. The residue obtained was purified by dry flash chromatography on silica gel (n-heptane/ethyl acetate, 7/3) to give a mixture of ,10aR)-6,6a,7,8,10,10a-hexahydro-1-hydroxy-6,6-dimethyl-3-pentyl-9H-dibenzo[b,d ]pyran-9-one, was improved by applying nitromethane as co-solvent. The final challenging step gave after a tuning of solvent dilution and amount of tetramethylethylenediamine at best a 6/4 mixture of [ 13 
